Analysts expect that Celsion Co. (NASDAQ:CLSN) will report earnings of ($0.36) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Celsion’s earnings. The lowest EPS estimate is ($0.48) and the highest is ($0.23). The firm is scheduled to announce its next earnings results on Tuesday, March 26th.
On average, analysts expect that Celsion will report full-year earnings of ($1.34) per share for the current financial year, with EPS estimates ranging from ($1.46) to ($1.21). For the next fiscal year, analysts forecast that the business will report earnings of ($0.94) per share, with EPS estimates ranging from ($1.21) to ($0.67). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Celsion.
Several equities research analysts have commented on CLSN shares. ValuEngine upgraded Celsion from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Zacks Investment Research cut Celsion from a “buy” rating to a “hold” rating in a research note on Tuesday, November 13th. Oppenheimer set a $9.00 target price on Celsion and gave the company a “buy” rating in a research note on Thursday, November 15th. Finally, Brookline Capital Management restated a “buy” rating on shares of Celsion in a research note on Tuesday, November 20th.
NASDAQ CLSN traded down $0.04 during trading on Thursday, hitting $2.23. The stock had a trading volume of 42,148 shares, compared to its average volume of 92,269. The stock has a market capitalization of $42.50 million, a price-to-earnings ratio of -0.93 and a beta of 2.14. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.84 and a current ratio of 3.84. Celsion has a 12 month low of $1.35 and a 12 month high of $3.48.
Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. increased its holdings in shares of Celsion by 21.9% during the 4th quarter. BlackRock Inc. now owns 142,426 shares of the biotechnology company’s stock worth $202,000 after acquiring an additional 25,548 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Celsion by 40.9% during the 3rd quarter. Vanguard Group Inc. now owns 740,132 shares of the biotechnology company’s stock worth $2,050,000 after acquiring an additional 214,829 shares during the last quarter. Finally, Vanguard Group Inc increased its holdings in shares of Celsion by 40.9% during the 3rd quarter. Vanguard Group Inc now owns 740,132 shares of the biotechnology company’s stock worth $2,050,000 after acquiring an additional 214,829 shares during the last quarter. Institutional investors own 6.90% of the company’s stock.
Celsion Company Profile
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer.
Featured Story: Why do companies pay special dividends?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.